Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (41)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Faivre, S.
Right arrow Articles by Raymond, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faivre, S.
Right arrow Articles by Raymond, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1479-1489, 2002
© 2002 European Society for Medical Oncology

Original Paper

Phase I–II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma

S. Faivre1, T. Le Chevalier1, C. Monnerat1, F. Lokiec2, S. Novello1, J. Taieb1, P. Pautier1, C. Lhommé1, P. Ruffié1, L. Kayitalire3, J.-P. Armand1 and E. Raymond1,+

1 Department of Medicine, Institut Gustave-Roussy, Villejuif; 2 Pharmacokinetic Unit, Centre René-Huguenin, St-Cloud; 3 Lilly France, Saint-Cloud, France

Received 7 January 2002; accepted 14 January 2002

Background:

The aim of this study was to determine the toxicity profile, the recommended dose (RD) and the pharmacokinetic parameters, and to evaluate the antitumor activity of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer (NSCLC) and ovarian carcinoma (OC).

Methods:

Gemcitabine was administered as a 30-min infusion followed by a 2-h infusion of oxaliplatin, repeated every 2 weeks. Doses of gemcitabine and oxaliplatin ranged from 800 to 1500 and 70 to 100 mg/m2, respectively.

Results:

Forty-four patients (26 males, 18 females; median age 55 years) including 35 NSCLC (five platinum pretreated) and nine OC patients (all platinum pretreated) received a total of 355 cycles. All patients were evaluable for toxicity. No dose-limiting toxicity at any dose level occurred during the first two cycles; therefore, the highest dose-level of gemcitabine (1500 mg/m2) and oxaliplatin (85 mg/m2) was considered as the RD. Hematological toxicity was moderate amongst the 22 patients treated (167 cycles) at that dose level. Thirteen cycles were associated with grade 3–4 non-febrile neutropenia in six patients, and eight cycles with grade 3–4 thrombocytopenia in two patients. Other toxicities were mild to moderate, consisting of asthenia and peripheral neurotoxicity. Four of the 35 patients treated with oxaliplatin 85 mg/m2 experienced grade 3 neurotoxicity requiring treatment discontinuation at cycle 10. In the range of the doses used, gemcitabine and its main metabolite 2',2'-difluorodeoxyuridine appeared not to be affected by oxaliplatin 70–100 mg/m2. Of the 44 patients evaluable for activity, 12 NSCLC patients experienced objective responses (one complete and 11 partial responses) and three OC patients showed tumor stabilization lasting for 6 months with a 50% decrease of CA 125 level. Two partial responses (NSCLC) and one tumor stabilization (OC) occurred in platinum-resistant patients.

Conclusions:

The combination of gemcitabine and oxaliplatin could be safely administered on an out-patient schedule in patients with advanced NSCLC and OC. The RD was gemcitabine 1500 mg/m2 and oxaliplatin 85 mg/m2 every 2 weeks. Promising antitumor activity was reported in patients with NSCLC and platinum-pretreated OC, and thus, deserves further evaluation.

Key words: anti-metabolite, combination chemotherapy, diaminocyclohexane, neurotoxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
B. B. Y. Ma, E. P. Hui, S. C. C. Wong, S. Y. Tung, K. K. Yuen, A. King, S. L. Chan, S. F. Leung, M. K. Kam, B. K. H. Yu, et al.
Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms
Ann. Onc., June 23, 2009; (2009) mdp065v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Bidoli, N Zilembo, D Cortinovis, L Mariani, L Isa, E Aitini, D Cullura, F Pari, P Nova, M Mancin, et al.
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study
Ann. Onc., March 1, 2007; 18(3): 461 - 467.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Faivre and E Raymond
Management of neuromuscular dose limiting toxicity at the early stage of drug development.
Ann. Onc., September 1, 2006; 17(9): 1343 - 1346.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. Theodore, F. Bidault, N. Bouvet-Forteau, M. Abdelatif, K. Fizazi, M. di Palma, P. Wibault, R. de Crevoisier, and A. Laplanche
A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract
Ann. Onc., June 1, 2006; 17(6): 990 - 994.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.